IGC Pharma (IGC) Enterprise Value (2010 - 2026)

IGC Pharma (IGC) has reported Enterprise Value for 17 consecutive years, with $25.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Enterprise Value rose 13.58% year-over-year to $25.7 million in Q1 2026; TTM through Mar 2026 was $25.7 million, a 13.58% increase from a year earlier, with the FY2026 full-year figure at $25.7 million, up 13.58% from the prior year.
• Enterprise Value was $25.7 million for Q1 2026 at IGC Pharma, up from $24.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at $38.0 million in Q1 2022 and troughed at $11.8 million in Q4 2022.
• A 5-year average of $23.5 million and a median of $24.9 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 74.04% in 2022 and surged 115.76% in 2024, its largest moves.
• Over 5 years, Enterprise Value stood at $11.8 million in 2022, then surged by 40.05% to $16.5 million in 2023, then soared by 56.65% to $25.8 million in 2024, then decreased by 3.51% to $24.9 million in 2025, then gained by 3.29% to $25.7 million in 2026.
• The last three Enterprise Value figures came in at $25.7 million (Q1 2026), $24.9 million (Q4 2025), and $37.2 million (Q3 2025), per Business Quant data.